Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Cogent Biosciences (COGT) EBT (2017 - 2021)

Cogent Biosciences has reported EBT over the past 5 years, most recently at -$25.5 million for Q4 2021.

  • Quarterly results put EBT at -$25.5 million for Q4 2021, down 124.27% from a year ago — trailing twelve months through Dec 2021 was -$75.1 million (up 8.5% YoY), and the annual figure for FY2025 was -$321.7 million, down 24.78%.
  • EBT for Q4 2021 was -$25.5 million at Cogent Biosciences, down from -$19.7 million in the prior quarter.
  • Over the last five years, EBT for COGT hit a ceiling of $2.3 million in Q4 2019 and a floor of -$57.2 million in Q3 2020.
  • Median EBT over the past 5 years was -$9.7 million (2018), compared with a mean of -$12.5 million.
  • Biggest five-year swings in EBT: soared 126.77% in 2019 and later crashed 594.78% in 2020.
  • Cogent Biosciences' EBT stood at -$6.8 million in 2017, then fell by 26.77% to -$8.6 million in 2018, then soared by 126.77% to $2.3 million in 2019, then crashed by 594.78% to -$11.4 million in 2020, then plummeted by 124.27% to -$25.5 million in 2021.
  • The last three reported values for EBT were -$25.5 million (Q4 2021), -$19.7 million (Q3 2021), and -$17.2 million (Q2 2021) per Business Quant data.